Consumers Beware: Risks of Femur Fractures and Fosamax

Fosamax is a prescription drug in the bisphosphonate family used to treat post menopausal women for osteoporosis and to increase bone mass in older men with osteoporosis.

Like most prescription drugs, Fosamax has serious quality-of-life threatening side effects. Yet, Fosamax has not been recalled – yet.

The Food & Drug Administration has issued a number of alerts for Fosamax but so far even though people suffer from esophageal cancer, osteonecrosis (jawbone death), long bone fractures of the femur, and possible atrial fibrillation – Fosamax remains in the marketplace.

Patients and healthcare professionals may have questions about oral bisphosphonate medications and atypical subtrochanteric femur fractures – fractures in the bone just below the hip joint.

Recent news reports have raised the question about whether there is an increased risk of this type of fracture in patients with osteoporosis using Fosamax. Even though studies prevail, the data that FDA has reviewed have not shown a clear connection between bisphosphonate use such as Fosamax and a risk of atypical subtrochanteric femur fractures.

However, the FDA is working closely with outside experts, including members of the recently convened American Society of Bone and Mineral Research Subtrochanteric Femoral Fracture Task Force, to gather additional information that may provide more insight into this issue in the future.

As the patient or a spouse or son or daughter of a parent or grandparent taking Fosamax, please take note:

• Do not stop taking your medication unless told to do so by your healthcare professional.
• Talk to your healthcare professional if you develop new hip or thigh pain or have any concerns with your medications.

Contact a Pennsylvania personal injury law firm with a strong track record zealously fighting for victims of unsafe drugs.

CALL TODAY 866.735.2792